A carregar...
Innovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A
Hemophilia A (coagulation factor VIII deficiency) is a debilitating genetic disorder that is primarily treated with intravenous replacement therapy. Despite a variety of factor VIII protein formulations available, the risk of developing anti-dug antibodies (“inhibitors”) remains. Overall, 20–30% of...
Na minha lista:
| Publicado no: | Front Immunol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5705551/ https://ncbi.nlm.nih.gov/pubmed/29225598 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2017.01604 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|